Skip to main content
Neuland Laboratories Limited. logo

Neuland Laboratories Limited. — Investor Relations & Filings

Ticker · NEULANDLAB ISIN · INE794A01010 LEI · 335800AVHZURTYQ17N08 BSE.NS Manufacturing
Open in API
Filings indexed 947 across all filing types
Latest filing 2020-05-22 Regulatory Filings
Country IN India
Listing BSE.NS NEULANDLAB

About Neuland Laboratories Limited.

https://www.neulandlabs.com

Neuland Laboratories Limited specializes in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and provides comprehensive Custom Manufacturing Solutions (CMS). The company focuses on complex chemistry and high-quality standards, operating state-of-the-art manufacturing facilities that comply with international regulatory requirements, including those of the USFDA and EDQM. Its product portfolio spans diverse therapeutic areas such as cardiovascular, central nervous system, anti-infectives, and antiasthmatics. Neuland supports pharmaceutical companies globally through the entire lifecycle of a drug, from early-stage clinical development to commercial-scale production. By leveraging advanced technical expertise and a robust quality management system, the organization delivers reliable chemical synthesis and process optimization services to both innovator and generic drug manufacturers.

Recent filings

Filing Released Lang Actions
Financial Result Updates
Regulatory Filings
2020-05-22 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is an announcement of an upcoming earnings call for Neuland Laboratories Limited regarding its Q4 and full year 2019-20 results. It provides details about the date, time, and dial-in numbers for the call but does not contain any actual financial data or detailed financial results. The document length is short (1907 characters) and it explicitly states that the results will be announced on May 22, 2020, followed by a conference call. This fits the profile of a Call Transcript announcement or an Earnings Release announcement. However, since this document is only announcing the earnings call and not the transcript or the earnings highlights themselves, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about the earnings call event, not the earnings release or transcript itself.
2020-05-18 English
Press Release
Report Publication Announcement Classification · 95% confidence The document is a notice of a Board Meeting scheduled for May 22, 2020, to consider and take on record the Audited Financial Results for the year ended March 31, 2020. It is a formal announcement sent to stock exchanges and published in a newspaper. The document does not contain the financial results themselves but only the notice of the meeting where these results will be discussed. The document length is 4625 characters, which is relatively short and consistent with a notice rather than a full report. Therefore, this is a Report Publication Announcement (RPA) type filing, as it announces the upcoming board meeting and the forthcoming financial results report, not the report itself.
2020-05-15 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a notice informing stock exchanges about an upcoming Board Meeting scheduled to consider and take on record the Audited Financial Results for the fiscal year ended March 31, 2020. It also mentions the trading window closure and reopening in compliance with insider trading regulations. The document is short (1688 characters) and serves as an announcement of a meeting rather than containing any financial data or the actual financial results. Therefore, it is not an Annual Report (10-K) or Earnings Release (ER), but rather a Regulatory Filing (RNS) as it is a general regulatory announcement to stock exchanges about the Board Meeting and related compliance matters.
2020-05-14 English
Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) informing them about the receipt of an Establishment Inspection Report (EIR) from the U.S. FDA following an inspection of a manufacturing facility. It references a prior letter and provides an update on the inspection closure. The document is short (1306 characters) and serves as an informational update rather than a detailed report or financial filing. It does not contain financial data, management discussion, or regulatory certifications. It is an announcement related to regulatory inspection results, which does not fit into categories like Annual Report, Interim Report, or Audit Report. It is best classified under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2020-05-07 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2020-04-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.